Degussa AG &lt;DGSG.F> said it planned aone-for-five rights issue at 225 marks per share, raisingnominal share capital by 61 mln marks, by the end of itscurrent business year ending September 30.    The company said in a statement it would also raise nominalshare capital by 20 mln marks in a share swap as part of itsplanned takeover of French medicine group &lt;Laboratoires SargetSA>.    The two capital measures will raise Degussa nominal sharecapital to 365 mln marks.    Degussa said last week it intended to buy 100 pct of thecapital of the medical pharmaceuticals group Sarget, based inMerignac near Bordeaux.    Sarget had 1986 sales in France, Belgium, the Netherlands,Spain, Portugal and Italy of 730 mln French francs.    Degussa has not said how much it would pay for Sarget, but20 mln marks nominal of 50-mark shares, at today's Frankfurtopening price of 494.70 marks, would be worth nearly 198 mlnmarks.    A 61 mln mark nominal capital increase at 225 marks wouldraise 274.5 mln marks.    Degussa said the 20 mln mark nominal capital increase wouldtake the form of an issue of shares for a non-cashconsideration. The April 10 annual meeting agreed that therewould be no rights issue on this capital, which was alreadyauthorized but unissued.    The rights issue involving the 61 mln mark nominal capitalincrease will be led by Dresdner Bank AG. Following thatcapital increase, Degussa would be left with 19 mln marks ofauthorized but unissued capital, a Degussa spokesman said.    Part of the 274.5 mln marks from the rights issue wouldalso be used for the Serget acquisition, he added. REUTER&#3;